Tecovirimat Use under Expanded Access to Treat Mpox in the United States, 2022–2023 | Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity—IVY Network, 26 Hospitals, 18 October 2023–9 March 2024
September 19, 2024 Read More »
Dr. Griffin’s article reveals the evidence regarding abnormalities and therapeutics for PASC and how to help
impacted individuals improve.
Comparison of protection against mpox following mRNA or modified vaccinia Ankara vaccination in nonhuman primates | Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials | Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial
September 12, 2024 Read More »
The Effect of Semaglutide on Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial |
Effectiveness of COVID-19 Vaccines to Prevent Long COVID: Data from Norway |
Fibrin Drives Thromboinflammation and Neuropathology in COVID-19 |
Post-Acute Sequelae of COVID (PASC or Long COVID): An Evidenced-based Approach
With over 240 episodes and counting, this conversational-style podcast
shares everything there is to know about the creatures that live in us, on us, and with us.
This Week in Parasitism: A Podcast About the Tiny Creatures that Live In and On Us Read More »
Effectiveness of Historical Smallpox Vaccination against Mpox Clade II in Men in Denmark, France, the Netherlands and Spain, 2022 |
Pemivibart is Less Active against Recent SARS-CoV-2 JN.1 Sublineages | U.S. Real-World Effectiveness Study of Nirmatrelvir/Ritonavir in Preventing Hospitalization of High-Risk COVID-19 Patients |
COVID-19 and Mental Illnesses in Vaccinated and Unvaccinated People | Post-acute COVID-19 Outcomes Including Participant-reported Long COVID: Amubarvimab/romlusevimab versus Placebo in the ACTIV-2 Trial
What Is the Economic Benefit of Annual COVID-19 Vaccination From the Adult | Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023–January 2024 | Uptake of COVID-19 vaccines and association with hospitalisation due to COVID-19 in pregnancy: Retrospective cohort study | The Novavax Heterologous Coronavirus Disease 2019 Booster Demonstrates Lower Reactogenicity Than Messenger | Characterizing Long COVID in Children and Adolescents
Onward Virus Transmission after Measles Secondary Vaccination Failure | Single Monoclonal Antibodies Should Not be Used for COVID-19 Therapy: A Call for Antiviral Stewardship |
Differentiation of Prior SARS-CoV-2 Infection and Postacute Sequelae by Standard Clinical Laboratory Measurements in the RECOVER Cohort | Risk Factors for Long COVID Syndrome in Postmenopausal Women with Previously Reported Diagnosis of COVID-19 |
Long-COVID Symptom Monitoring: Insights from a Two-year Telemedicine Study
While parasitic diseases can be treated, much of the medical community doesn’t have the necessary knowledge to help those infected. The founders of Parasites Without Borders are on a mission to change that and to help eliminate human suffering from parasitic infections.
Parasitology: Picking Up Where Medical School Left Off Read More »
A comprehensive educational resource on all aspects of parasitic diseases and their impact on humanity around the globe.
Help bring the latest medical and basic biological information pertaining to diseases caused by eukaryotic parasites to every practicing physician and medical student within the United States.
English 
Spanish 